251 research outputs found

    Tema Con Variazioni: Quantum Channel Capacity

    Full text link
    Channel capacity describes the size of the nearly ideal channels, which can be obtained from many uses of a given channel, using an optimal error correcting code. In this paper we collect and compare minor and major variations in the mathematically precise statements of this idea which have been put forward in the literature. We show that all the variations considered lead to equivalent capacity definitions. In particular, it makes no difference whether one requires mean or maximal errors to go to zero, and it makes no difference whether errors are required to vanish for any sequence of block sizes compatible with the rate, or only for one infinite sequence.Comment: 32 pages, uses iopart.cl

    High-resolution cryo-EM structures of respiratory complex I : Mechanism, assembly, and disease

    Get PDF
    Respiratory complex I is a redox-driven proton pump, accounting for a large part of the electrochemical gradient that powers mitochondrial adenosine triphosphate synthesis. Complex I dysfunction is associated with severe human diseases. Assembly of the one-megadalton complex I in the inner mitochondrial membrane requires assembly factors and chaperones. We have determined the structure of complex I from the aerobic yeast Yarrowia lipolytica by electron cryo-microscopy at 3.2-angstrom resolution. A ubiquinone molecule was identified in the access path to the active site. The electron cryo-microscopy structure indicated an unusual lipid-protein arrangement at the junction of membrane and matrix arms that was confirmed by molecular simulations. The structure of a complex I mutant and an assembly intermediate provide detailed molecular insights into the cause of a hereditary complex I-linked disease and complex I assembly in the inner mitochondrial membrane.Peer reviewe

    High-resolution cryo-EM structures of respiratory complex I : Mechanism, assembly, and disease

    Get PDF
    Respiratory complex I is a redox-driven proton pump, accounting for a large part of the electrochemical gradient that powers mitochondrial adenosine triphosphate synthesis. Complex I dysfunction is associated with severe human diseases. Assembly of the one-megadalton complex I in the inner mitochondrial membrane requires assembly factors and chaperones. We have determined the structure of complex I from the aerobic yeast Yarrowia lipolytica by electron cryo-microscopy at 3.2-angstrom resolution. A ubiquinone molecule was identified in the access path to the active site. The electron cryo-microscopy structure indicated an unusual lipid-protein arrangement at the junction of membrane and matrix arms that was confirmed by molecular simulations. The structure of a complex I mutant and an assembly intermediate provide detailed molecular insights into the cause of a hereditary complex I-linked disease and complex I assembly in the inner mitochondrial membrane.Peer reviewe

    Scorpionfish BPI is highly active against multiple drug-resistant Pseudomonas aeruginosa isolates from people with cystic fibrosis

    Get PDF
    Chronic pulmonary infection is a hallmark of cystic fibrosis (CF) and requires continuous antibiotic treatment. In this context, Pseudomonas aeruginosa (Pa) is of special concern since colonizing strains frequently acquire multiple drug resistance (MDR). Bactericidal/permeability-increasing protein (BPI) is a neutrophil-derived, endogenous protein with high bactericidal potency against Gram-negative bacteria. However, a significant range of people with CF (PwCF) produce anti-neutrophil cytoplasmic antibodies against BPI (BPI-ANCA), thereby neutralizing its bactericidal function. In accordance with literature, we describe that 51.0% of a total of 39 PwCF expressed BPI-ANCA. Importantly, an orthologous protein to human BPI (huBPI) derived from the scorpionfish Sebastes schlegelii (scoBPI) completely escaped recognition by these autoantibodies. Moreover, scoBPI exhibited high anti-inflammatory potency towards Pa LPS and was bactericidal against MDR Pa derived from PwCF at nanomolar concentrations. In conclusion, our results highlight the potential of highly active orthologous proteins of huBPI in treatment of MDR Pa infections, especially in the presence of BPI-ANCA

    Partial Anterior Cruciate Ligament Ruptures: Advantages by Intraligament Autologous Conditioned Plasma Injection and Healing Response Technique—Midterm Outcome Evaluation

    Get PDF
    The historical treatment options for partial anterior cruciate ligament (ACL) ruptures were conservative therapy or ACL reconstruction by injured bundle or entire ACL replacement. In awareness of the regenerative potential of biologic agents such as mesenchymal stem cells or platelet rich plasma (PRP), the healing response technique was developed to preserve the injured ACL with belter outcomes lhan ihe conservative therapy. Further improvement of this technique seems to be obtained by the additional application of PRP products. Thus, the aim of this study was to evaluate the midterm outcome after intraligament autologous conditioned plasma (ACP) by a clinical, scoring, and functional performance assessment. 42 patients were evaluated in this study. The failure rate was 9.5%. Outcome evaluation showed good to excellent results. The scores were IKDC subjective 83.2 (SD 14.5), Lysholm 85.5 (SD 15.5), Tegner 4.7 (SD 1.7), and Cincinnati 85.4 (SD 15.5) afler a mean follow-up of 33 months. Clinical examination showed stable Lachman tesl, negative pivot shift phenomenon, and a significant reduction in AP-laxity compared to preoperative status (rolimeter preoperative: 1.9 (SD1.4); postoperative 0.6 (SD1.8), p=0.001) in all patients. Functional performance testing showed no significant differences between the injured and healthy side. Return to sport was achieved after a mean of 5.8 months (SD 3.6) in 71.1% of the included patients. In summary, this new treatment option revealed in midterm follow-up promising results to treat partial ACL lesions with a reduced need for conversion to ACL reconstruction and with a high percentage of return to preinjury sport activity

    Determination of the Michel Parameters rho, xi, and delta in tau-Lepton Decays with tau --> rho nu Tags

    Full text link
    Using the ARGUS detector at the e+e−e^+ e^- storage ring DORIS II, we have measured the Michel parameters ρ\rho, Ο\xi, and ΟΎ\xi\delta for τ±→l±ΜΜˉ\tau^{\pm}\to l^{\pm} \nu\bar\nu decays in τ\tau-pair events produced at center of mass energies in the region of the ΄\Upsilon resonances. Using τ∓→ρ∓Μ\tau^\mp \to \rho^\mp \nu as spin analyzing tags, we find ρe=0.68±0.04±0.08\rho_{e}=0.68\pm 0.04 \pm 0.08, Οe=1.12±0.20±0.09\xi_{e}= 1.12 \pm 0.20 \pm 0.09, ΟΎe=0.57±0.14±0.07\xi\delta_{e}= 0.57 \pm 0.14 \pm 0.07, ρΌ=0.69±0.06±0.08\rho_{\mu}= 0.69 \pm 0.06 \pm 0.08, ΟΌ=1.25±0.27±0.14\xi_{\mu}= 1.25 \pm 0.27 \pm 0.14 and ΟΎΌ=0.72±0.18±0.10\xi\delta_{\mu}= 0.72 \pm 0.18 \pm 0.10. In addition, we report the combined ARGUS results on ρ\rho, Ο\xi, and ΟΎ\xi\delta using this work und previous measurements.Comment: 10 pages, well formatted postscript can be found at http://pktw06.phy.tu-dresden.de/iktp/pub/desy97-194.p

    New Philharmonia Chorus, de Londres, director adjunto: Russell Burgess, Orquesta Nacional, Rafael FrĂŒbeck de Burgos director

    Get PDF
    Programa dels concerts que va dur a terme l'Orquestra Nacional d'Espanya amb el New Philharmonia Chorus de Londres, dirigits per R. FrĂŒhbeck de Burgos i R. Burgess respectivament. En primer lloc van interpretar "Elies" de F. Mendelssohn, amb E. Speiser, N. Procter, W. Hollweg i H. Hagegard com a solistes, i amb M. Torrent a l'orgue. El proper concert van interpretar "La CreaciĂł" de J. Haydn, amb H. Donath, W. Hollweg i S. Nimsgern com a solistes. Els concerts es van celebrar en el marc de la XIV temporada musical del patronat pro musica de Barcelon

    A Search for the Electric Dipole Moment of the Tau-Lepton

    Full text link
    Using the ARGUS detector at the e+e- storage ring DORIS II, we have searched for the real and imaginary part of the electric dipole formfactor d_tau of the tau lepton in the production of tau pairs at q^2=100 GeV^2. This is the first direct measurement of this CP violating formfactor. We applied the method of optimised observables which takes into account all available information on the observed tau decay products. No evidence for CP violation was found, and we derive the following results: Re(d_tau)=(1.6+-.9)*10^(-16) ecm and Im(d_tau)=(-0.2+-0.8)*10^(-16) ecm, where statistical and systematic errors have been combined.Comment: 8 pages, 5 figures (10 subfigures

    Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged‐Release Ketamine With Emphasis on 2,6‐Hydroxynorketamines

    No full text
    Abstract Modeling of metabolite kinetics after oral administration of ketamine is of special interest because of the higher concentrations of active metabolites because of the hepatic first‐pass effect. This holds especially in view of the potential analgesic and antidepressant effects of 2R,6R‐ and 2S,6S‐hydroxynorketamine at low doses of ketamine. Therefore, a 9‐compartment model was developed to analyze the pharmacokinetics of ketamine enantiomers and their metabolites after racemic ketamine administered intravenously (5 mg) and as 4 doses (10, 20, 40, and 80 mg) of a prolonged‐release formulation (PR‐ketamine). Using a population approach, the serum concentration‐time data of the enantiomers of ketamine, norketamine, dehydronorketamine, and 2,6‐hydroxynorketamine obtained in 15 healthy volunteers could be adequately fitted. The estimated model parameters were used to simulate serum concentration‐time profiles; after multiple dosing of PR‐ketamine (2 daily doses of 20 mg), the steady‐state concentrations of R‐ and S‐ketamine were 1.4 and 1.3 ng/mL, respectively. The steady‐state concentration of 2R,6R‐hydroxynorketamine exceeded those of R‐norketamine (4‐fold), R‐dehydonorketamine (8‐fold), and R‐ketamine (46‐fold), whereas that of 2S,6S‐hydroxynorketamine exceeded that of S‐ketamine by 14‐fold. The model may be useful for identifying dosing regimens aiming at optimal plasma concentrations of 2,6‐hydroxynorketamines
    • 

    corecore